BMY Extends Dividend Raise Streak to 18 Consecutive Years
What happened
Bristol-Myers Squibb has raised its dividend for 18 straight years, according to a Motley Fool analysis published June 11. The piece highlights a specific financial metric the publication argues supports the continuation of that streak. BMY is a major pharmaceutical company whose portfolio includes oncology and immunology drugs. Dividend continuity for large-cap pharma names typically depends on free cash flow coverage ratios and pipeline revenue sustainability.
The QL Read
QuantLogix composite reads 62/100 with BMY shares up 2.34% on the session to $56.90. The next quarterly earnings report will offer a fresh read on free cash flow coverage relevant to the dividend trajectory.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.